![Pedro Reiser](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pedro Reiser
Keine laufenden Positionen mehr
Karriereverlauf von Pedro Reiser
Ehemalige bekannte Positionen von Pedro Reiser
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Vorsitzender | 01.01.2002 | 01.01.2004 |
Holvis AG
![]() Holvis AG Pulp & PaperProcess Industries Part of Signature Aviation US Topco LLC, Holvis AG is a paper concern. The company is based in Basel, Switzerland. Holvis was acquired by Signature Aviation Ltd., part of Signature Aviation US Topco LLC from June 01, 2021 on June 01, 1995 for $404.89 million. | Präsident | 01.01.1990 | 01.01.1995 |
Ausbildung von Pedro Reiser
University of Zurich | Undergraduate Degree |
University of Geneva | Doctorate Degree |
Statistik
International
Schweiz | 5 |
Operativ
Chairman | 1 |
President | 1 |
Undergraduate Degree | 1 |
Sektoral
Consumer Services | 3 |
Process Industries | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Holvis AG
![]() Holvis AG Pulp & PaperProcess Industries Part of Signature Aviation US Topco LLC, Holvis AG is a paper concern. The company is based in Basel, Switzerland. Holvis was acquired by Signature Aviation Ltd., part of Signature Aviation US Topco LLC from June 01, 2021 on June 01, 1995 for $404.89 million. | Process Industries |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
- Börse
- Insiders
- Pedro Reiser
- Erfahrung